Real-world analysis reveals treatment sequencing, healthcare resource utilization, and outcomes in mantle cell lymphoma patients.
Key Points
A significant proportion of mantle cell lymphoma patients were treated with bendamustine and venetoclax in the first line, leading to important clinical outcomes.
Healthcare resource utilization remains high across treatment lines, with varied outpatient and inpatient service usage among different regimens.
Treatment patterns demonstrated an increased use of Bruton tyrosine kinase inhibitors over time, indicating a shift in therapy strategies.
The findings emphasize the need for novel therapeutic options, particularly in heavily pretreated population.